Immutep Ltd ADR IMMP

$3.17 -0.11 (-3.35%)

Valuation

Market cap
24,176,000
Revenue TTM
$16,400,000
Net income TTM
$-53,820,000
PE ratio
0.00
Forward PE
—
Profit margin
-328.17%
Debt to equity
0.00

Trading

Volume
7,500
Avg volume
17,601
Day's range
$3.07 – $3.27
Shares out
7,371,000
Stochastic %K
17%
Beta
2.27
Analysts
Strong Sell
Price target
$30.00

Price

Company profile

Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed a...

Show more

Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (1L HNSCC); an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in patients with early-stage HR+/HER2-negative breast cancer; and EFTISARC-NEO, which is in a Phase II clinical trial for the treatment of soft tissue sarcoma. In addition, the company develops INSIGHT-003, which is in a Phase I trial for 1L non squamous non-small cell lung cancer (NSCLC); EOC 202, which has completed a Phase I trial for metastatic breast cancer; IMP761, an agonist LAG-3 antibody in a Phase I trial; IMP731, a LAG-3 depleting antibody that has completed a Phase II trial for ulcerative colitis and a Phase I trial for psoriasis; and ieramilimab/LAG525/IMP701, which are anti-LAG-3 antagonist antibodies. It has collaborations with Merck & Co., Inc., Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, the Maria Sklodowska-Curie National Research Institute of Oncology, EOC Pharma, Dr Reddy's Laboratories, Monash University, and George Washington University. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

Industry
Biotechnology
Sector
Healthcare
Phone
61 2 8315 7003
Website
https://www.immutep.com
Address
Australia Square, Level 32, Suite 32.07 264 George Street, Sydney, Australia

Latest news

Stocktwits

ToRni27 Oct 22, 11:04 PM
$IMMP nahhh if they just had manufactoring issues than they should reintroduce a phase 3 lung cancer trial. If the drug is working but was not produced properly for the study than they should redo it ofc. Otherwise I believe the drug is not working. GL!
1 replies
rispi Oct 22, 8:18 AM
$IMMP meanwhile in Aussiland Immutep Ltd (IMM) AUD 0,022 -0,002 (-8,33%)
1 replies
rispi Oct 21, 8:05 AM
$IMMP 3.6200 0.36 11.04% Before Hours Volume: 8
0 replies
M31V1 Oct 20, 6:12 AM
$IMMP Merck is the most logical strategic buyer based on the length of the efti + Keytruda collab. The remaining pipeline is effectively priced at a negative value creating a valuation gap relative to the residual assets in PD L1 negative HNSCC and neoadjuvant STS plus the existing relationship with Merck. IMO, a $500M equity value is achievable where manufacturing questions are resolved and Phase II pathways are clarified. It would represent a material premium.
0 replies
LAG3boom Oct 19, 2:03 PM
$IMMP https://markets.businessinsider.com/news/stocks/immutep-announces-late-breaking-abstract-on-imp761-accepted-for-poster-presentation-at-acr-convergence-2026-1036638696 😎
0 replies
ToRni27 Oct 17, 11:58 PM
$IMMP when next R/S? We are close again 😂 When OTC market? 😂
0 replies
ToRni27 Oct 17, 11:57 PM
$IMMP when zero? Can you die already… stupid stock! 😁💪💯
0 replies
rispi Oct 16, 10:08 AM
$IMMP Which kind of value for shareholder are talking about???
0 replies